Holen Sie sich die Stockscreener-App
40.39
1.75%
-0.72
Handel nachbörslich:
39.00
-1.39
-3.44%
Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor in Plaque Psoriasis - WSIL TV
Protagonist Therapeutics Enters Oversold Territory (PTGX) - Nasdaq
Protagonist's Psoriasis Drug Shows 74% Success Rate, Secures $165M Milestone Payment | PTGX Stock News - StockTitan
Janney Montgomery Scott LLC Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Amalgamated Bank Buys 15,301 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
What is HC Wainwright’s Forecast for PTGX FY2024 Earnings? - Defense World
HC Wainwright Analysts Increase Earnings Estimates for PTGX - MarketBeat
HC Wainwright Brokers Decrease Earnings Estimates for PTGX - Defense World
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
HC Wainwright Issues Pessimistic Estimate for PTGX Earnings - MarketBeat
US Bancorp DE Lowers Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Earns Buy Rating from HC Wainwright - MarketBeat
New York State Teachers Retirement System Invests $1.11 Million in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
New York State Teachers Retirement System Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month High – Should You Buy? - Defense World
Creative Planning Acquires New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
What is Wedbush’s Forecast for PTGX Q3 Earnings? - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week HighWhat's Next? - MarketBeat
Protagonist Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com UK
What is Wedbush's Estimate for PTGX Q3 Earnings? - MarketBeat
Protagonist Therapeutics Inc (PTGX) Q3 2024 Earnings: EPS Loss o - GuruFocus.com
Protagonist Therapeutics: Q3 Earnings Snapshot - San Francisco Chronicle
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Joplin Globe
Protagonist (PTGX) Reports $583M Cash Position, Key Trial Results Due Q4 2024 | PTGX Stock News - StockTitan
Financial Enhancement Group LLC Purchases Shares of 41,818 Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Wedbush Initiates Coverage of Protagonist Therapeutics (PTGX) with Outperform Recommendation - MSN
Wedbush Reiterates “Outperform” Rating for Protagonist Therapeutics (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Shares Down 5.4%Here's What Happened - MarketBeat
Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting - Weatherford Democrat
Protagonist's Rusfertide Phase 2 Trial Results Set for Major ASH Meeting Reveal | PTGX Stock News - StockTitan
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World
Vanguard Group Inc's Strategic Acquisition in Protagonist Therap - GuruFocus.com
Protagonist Therapeutics (NASDAQ:PTGX) Given Outperform Rating at Wedbush - MarketBeat
Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Price Target at $52.83 - Defense World
State of Alaska Department of Revenue Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Louisiana State Employees Retirement System Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) shareholders are still up 353% over 5 years despite pulling back 3.0% in the past week - Simply Wall St
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Allspring Global Investments Holdings LLC Increases Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Allspring Global Investments Holdings LLC Buys 103,414 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics stock hits 52-week high at $48.34 By Investing.com - Investing.com South Africa
Protagonist Therapeutics stock hits 52-week high at $48.34 - Investing.com India
Cavalier Investments LLC Purchases New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Short Interest Update - MarketBeat
Cwm LLC Increases Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Moody Aldrich Partners LLC Sells 14,928 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Bleakley Financial Group LLC Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
(PTGX) Investment Report - Stock Traders Daily
Protagonist Therapeutics Inc (PTGX) Stock Price & Chart | Trade Now - Capital.com
Swedbank AB Purchases New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics Inc. (PTGX): Advancing Treatments for Autoimmune Diseases - Insider Monkey
State Street Corp's Strategic Acquisition in Protagonist Therapeutics Inc - Yahoo Finance
State Street Corp's Strategic Acquisition in Protagonist Therape - GuruFocus.com
The Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is Pricey (PTGX) - Seeking Alpha
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):